Peter Sidaway

1 month ago | nature.com | Peter Sidaway

Most patients undergoing surgery for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer will require chemotherapy; however, the optimum approach, including the most effective regimen and whether perioperative chemotherapy is more effective than an adjuvant-only approach, remains uncertain. Now, 5-year follow-up data from the phase III RESOLVE trial provide evidence supporting the use of adjuvant S-1 plus oxaliplatin (SOX) in these patients.

2 months ago | nature.com | Peter Sidaway

Most women with newly diagnosed breast cancer remain alive and recurrence-free for many years after complete surgical resection. Thus, whether all these women require annual follow-up mammography remains uncertain. Now, data from the phase III Mammo-50 trial demonstrate that most women can safely undergo follow-up mammography at 2-yearly or 3-yearly intervals.

2 months ago | nature.com | Peter Sidaway

Patients with resectable mid–low rectal cancers often undergo total mesorectal excision (TME) surgery. Over the past decade, considerable research interest has been focused on minimally invasive TME procedures that might offer improved perioperative outcomes and preservation of sphincter function, including laparoscopic and transanal approaches. Despite some evidence of an increased risk of local recurrence with the transanal approach, only limited data on long-term outcomes are available.

Jan 2, 2025 | nature.com | Peter Sidaway

Axillary nodal status provides important information on the prognosis of women with invasive breast cancer. However, the required sentinel lymph node biopsy sampling procedure and the associated risks of surgical complications have raised questions regarding the necessity of this procedure in women undergoing breast-conserving surgery for early stage disease. Now, data from INSEMA, a prospective, randomized, non-inferiority trial, confirm that this procedure can safely be avoided.

Dec 17, 2024 | nature.com | Peter Sidaway

Despite considerable progress, B-cell acute lymphoblastic leukaemia (B-ALL) remains a major cause of cancer-related death in children. Now, data from the phase III AALL1731 trial demonstrate that adding the CD19 × CD3 bispecific T cell engager blinatumomab to chemotherapy significantly improves the outcomes of patients with standard-risk B-ALL with an average or high risk of disease relapse.